Article

ASCO 2012 ... the latest in cancer research

Author(s):

Elizabeth Whittington

We are all gearing up for the largest oncology meeting of the year, the annual meeting of the American Society of Clinical Oncology. What's great about this meeting is we hear both the up-and-coming, early phase studies, but also the late-phase studies. These studies could truly change clinical practice for patients.If you have a minute, take a look at the ASCO schedule and let us know if there is anything that you want to know more about!

Related Videos
Adolescent and Young Adult Cancer Awareness Week sheds light on the financial hardships young cancer survivors face, including debt and limited assistance.
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
Image of woman.
Image of woman.
Image of woman.
Image of woman.
Image of man wearing baseball cap backwards.
Image of smiling doctor.
Related Content
Dr. Surbhi Sidana discussed the topic of minimal residual disease: nobeastsofierce - stock.adobe.com
April 1st 2025

What Role Does MRD Play in Multiple Myeloma Treatment Decision Making?

Alex Biese
Dr. Surbhi Sidana discussed the topic of minimal residual disease during the CURE Educated Patient® Multiple Myeloma Summit.
The Importance of Spotting Endometrial Cancer
March 18th 2025

The Importance of Spotting Endometrial Cancer

Endometrial cancer is on the rise. Hear survivor Angélica and Eisai Inc.'s Teresa Cronin discuss the Spot Her® initiative, which empowers women to spot early signs. This episode is sponsored by Eisai.
Image of chester.
April 1st 2025

What To Know About Having Radiation for Metastatic Prostate Cancer

Chester Freeman
As a caregiver, I learned that CyberKnife radiation for metastatic prostate cancer comes with psychological and physical challenges.
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
September 20th 2024

ROS1+ Non-Small Cell Lung Cancer: Progress in Care

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.
Tovecimig elicited responses in biliary tract cancer in the COMPANION-002 study: © LIGHTFIELD STUDIOS - stock.adobe.com.
April 1st 2025

Second-Line Tovecimig Elicits Responses in Biliary Tract Cancer

Alex Biese
Treatment with tovecimig, formerly known as CTX-009, elicited responses in patients with biliary tract cancer, according to COMPANION-002 study results.
Illustration of lungs.
April 1st 2025

Tagrisso May Improve Survival in Advanced EGFR-Mutant NSCLC

Alex Biese
Tagrisso is associated with positive outcomes among patients with unresectable stage 3 EGFR-mutant non-small cell lung cancer.